Designing Growth Strategies is in our DNA

RNA interference (RNAi) Therapeutics Market Size, Share, and Industry Analysis, By Product (ONPATTRO, AMVUTTRA, GIVLAARI, OXLUMO, LEQVIO, RIVFLOZA, and QFITLIA, and Others), By Molecule Type (siRNA, shRNA, miRNA-based Therapeutics, and Others), By Therapeutic Area (Cardiometabolic Diseases, Rare Genetic Diseases, Hepatic Diseases, Oncology, and Others), By Route of Administration (Subcutaneous, Intravenous, and Others), By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail/Online Pharmacies, and Others), and Regional Forecast till 2034

Last Updated :September 22, 2026 | Format:PDF | Report ID: 119228

 

Ask Queries

man icon
Mail icon
Mail icon
What's included in this sample
Market segmentation:

Detailed and granular segments, regions and countries covered

Scope of research:

Comprehensive quantitative data and qualitative insights

Report structure:

Representation of data and insights in the report

Key findings:

Market Estimates, Growth Rate, Largest Region and Segment

Index:

Overview of data and insights in each chapter

Research Methodology:

Summary of research processes adopted

Companies Who Rely On Us For Their Market Research Needs
3M
abbvie
Amgen
Ansell
Fresenius
Galemed
Grifols
Ipsos
iqvia
Johnson
  • Ongoing
  • 2025
  • 2021-2024